Page 343 - ASHG 2012 Annual Meeting Program Guide

330
SPEAKER AND AUTHOR DISCLOSURES
Abecasis, G., University of Michigan/ArticDx - 7;
GlaxoSmithKline - 2 (Session 7)
Ahmed, A., Genzyme Corporation - 2 (715)
Andersen, M., Life Technologies - 3;
Life Technologies - 1 (1237)
Aradhya, S., GeneDx - 3 (332)
Bachmeyer, R. C., Kailos Genetics Inc. - 1, 3, 4, 6 (3527)
Bai, R., GeneDx - 3 (330)
Ballif, B. C., Signature Genomic Laboratories,
PerkinElmer, Inc., Spokane, - 3 (884)
Basel-Vanagaite, L., FDNA Ltd., Herzlyia, Israel - 5 (3185)
Bauer, P., Actelion Pharmaceuticals Ltd - 5 (684)
Baxter, S., GeneDx - 3 (1676)
Bergstrom Lucas, A., Agilent Technologies - 3 (3726)
Berman, J. R., Bio-Rad Laboratories - 3 (3690)
Bianchi, D., Verinata Health, Inc. - 1, 2, 5, 11, 12;
McGraw-Hill - 7; Wiley-Blackwell - 3 (Session 79)
Bibikova, M., Illumina, Inc. - 1, 3 (1238)
Biesecker, L. G., Wiley Blackwell - 5; Illumina Corp - 6
(
Session 73)
Billaud, J., Ingenuity Systems - 3 (3677)
Bishop, J., Life Technologies - 3 (3719)
Blangero, J., Eli Lilly and Co - 2 (Session 8)
Bloom, R. J., Agilent Technologies - 9, 12; Pacific
Biosciences - 9, 12 (3659)
Bombard, A. T., Sequenom, Inc. - 1, 3; UCSD - 3, 12
(
Session 79)
Bostick, M., Clontech Laboratories, Inc - 3 (3727)
Boyar, F. Z., Quest Diagnostics - 3, 10;
Genomic Vision - 10, 12 (3522)
Boysen, C., CLC bio - 3 (3528)
Bready, B., Nabsys - 1, 3, 4, 10, 13 (3529)
Brown, M. P. S., Pacific Biosciences of California -
1, 3 (36)
Brownstein, C. A., Boston Children’s Hospital - 3 (1769)
Busche, S., WaferGen - 12 (256)
Carulli, J. P., Biogen Idec - 1, 2, 3, 12 (2561)
Casanova, J.-L., Sanofi-Aventis - 5, 11; Merck - 5
(
Session 80)
Casuga, I., Ion Torrent/Life Technologies - 3 (3278)
Chao, E. C., Ambry Genetics - 3 (2907)
Cheng, S., Genzyme, a Sanofi Company - 1, 3, 10
(793)
Chiabai, M. A., CNPq - 2; FAP-DF - 2 (1202)
Cho, J. H., Pfizer - 5 (Session 80)
Chowdry, A. B., 23andMe Inc. - 1, 3 (1620)
Cipriani, V., Cambridge Enterprise on behalf of
Cambridge University - 10; UCL business on behalf
of University College London - 10 (2072)
Conklin, B., iPierian Inc - 1 (Session 78)
Conley, Y. P., University of Pittsburgh - 10 (1963)
Costa, P., Agilent Technologies - 3 (922)
Dai, X., Academy of Finland - 2; University of
Helsinki - 3; Chancellor’s Travel Grant - 14 (1265)
DaRe, J., Transgenomic, Inc. - 1, 3 (688)
Darnell, R. B., MSKCC (cloning Ri antigen) -
7 (
Session 24)
Davidson, C., Life Technologies - 3 (3684)
De La Vega, F., Omicia, Inc. - 1, 3, 5 (1770)
Delio, M., NIH Grant Support - 2 (1494)
de Paor, A., Irish Research Council for the Humanities
&
Social Sciences - 2 (1812)
Dermitzakis, E. T., DNAnexus - 11 (561)
Dewey, F., Personalis - 5 (1601)
Dickson, P., BioMarin - 2; Genzyme - 2 (785)
Durand, E. Y., 23andMe, Inc. - 3 (179)
Eberle, M. A., Illumina - 1, 3 (942)
Ehm, M. G., GlaxoSmithKline - 1, 2 (649)
Eicher, J. D., J.S. Genetics - 1, 4, 7, 10, 11 (1973)
Elboudwarej, E., Novartis - 5; Genentech - 5;
Sanofi-Aventis - 5; GlaxoSmithKilne - 5 (3454)
Erez, A., Neogenis - 12 (165)
Eriksson, N., 23andMe - 1, 3 (114); Boehringer
Ingelheim - 12 (619)
Fagerholm, R., On-Q-ity Inc. - 12 (1171)
Falk, M. J., United Mitochondrial Disease
Foundation - 6 (2943)
Feinerman, B., StemCellRegenMed - 3 (792)
Francke, U., 23andMe, Inc. - 3 (1782)
Friedlander, C., Fluidigm Incorp. - 1, 3 (3652)
Gai, X., Agilent - 12 (3653)
Gajecka, M., PerkinElmer, Inc., Spokane - 3 (934)
Ganesh, S. K., Affymetrix - 11; BioGen Idec - 11 (1639)
Geiss, G., Nanostring Technologies - 1, 3, 10 (1039)
Germain, D. P., Amicus Therapeutics - 14 (772)
Gilbert, D., VitaPath Genetics, Inc. - 1, 3 (75)
Goizet, C., Genzyme - 2, 14; Shire - 14; Actelion -
14 (716)
Goker-Alpan, O., Shire HGT - 3, 14, (768)
Gonzalez, K. D., Ambry Genetics - 3 (3065)
Green, R. C., 23andMe, Inc. - 9, 12; Pathway
Genomics Corporation - 12 (1825)
Guettouche, T., Caliper - 12; Ion Torrent/Life
Technologies - 14 (3706)
Gunter, C., Kailos Genetics - 5 (Session 81)
Hageman, G. S., Sequenom Inc - 5, 11;
Optherion Inc - 10, 15; shareholder (Session 7)
Hagerman, P., US Patent Office - 10; Pacific
Biosciences - 5, 13 (477)
Hagerman, R., Novartis - 2; Roche - 2; Seaside
Therapeutics - 2 (770)
Hart, R. K., Locus Development, Inc. - 1, 3, 4, 10, 13
(3548)
Hartshorne, T., Life Technologies - 3 (1146)
Heckerman, D., Microsoft - 1, 3 (1379)
Hegde, M., RainDance - 11; GenomeQuest - 11
(
Session 3)
High, K., BioMarin Pharmaceuticals - 5; Bluebird Bio,
Inc. - 1, 5; Bristol-Myers Squibb - 5; Elsevier - 7;
Genzyme, Inc. - 11; INSERM - 15 tool; Jackson
Laboratories - 15; McGraw Hill - 7; Nordic Biotech - 5;
Novo Nordisk - 14, ); PTC Therapeutics - 12;
Sangamo Biosciences|Life Sci (Session 23)
Hirschhorn, J. N., Pfizer - 2 (Session 2, Session 81)
Hoffman, J., Good Start Genetics - 2; Genzyme
Therapeutics - 2 (1729)
Hogg, G., Sequenom Center for Molecular Medicine -
3;
Sequenom, Inc. - 3 (2973)
Hoglund, B. N., Roche Molecular Systems - 3 (3713)
Hollox, E. J., Pfizer - 2 (Session 22)
Holstege, H., Life Technologies - 12 (494)
Huang, A., Verinata Health, Inc. - 3 (3007)
Ibrahim, J., Shire HGT - 3, 14 (769)
Jacob, H., Primary Genetics - 4 (Session 3)
Jansen Spayd, K., Kailos Genetics Inc. - 3 (1245)
Javed, A., Gene Link, Inc - 3 (2631)